Literature DB >> 11400147

Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications.

P Matthews1, C J Jones, J Skinner, M Haughton, C de Micco, D Wynford-Thomas.   

Abstract

Despite several recent studies, the biological status and clinical relevance of telomerase expression in tumours derived from the thyroid follicular cell remain controversial. This study has analysed a series of normal, benign, and malignant thyroid samples using two novel approaches: the use of purified epithelial cell fractions to eliminate false-positives due to telomerase-positive infiltrating lymphocytes; and the simultaneous measurement of telomere length to provide a clearer interpretation of telomere dynamics in thyroid neoplasia. The data obtained support the prediction that the epithelial component of non-neoplastic thyroid and of follicular adenomas is telomerase-negative, any positive results being explicable by lymphocyte infiltration. In contrast, many malignant tumours, both follicular and papillary, were telomerase-positive. However, serial dilution of extracts indicated a wide spectrum of activity in these cancers, possibly related to variation in the proportion of telomerase-positive cells. Furthermore, an unexpectedly high proportion were telomerase-negative, a finding which was not explicable by technical problems such as TRAP (telomeric repeat amplification protocol) assay sensitivity. Many of these apparently telomerase-negative tumours had abnormally long telomeres. Correlation of telomerase and telomere length data suggests that thyroid cancers fall into three biological groups: telomerase-positive lesions, consistent with the conventional model of telomere erosion followed by telomerase reactivation; telomerase-negative tumours, which maintain telomere length by a mechanism independent of telomerase; and telomerase-negative tumours which are still undergoing telomere erosion and may therefore be composed of mortal cancer cells. From a clinical standpoint, it is concluded that telomerase detection on unfractionated tissue, such as fine needle aspirates, is of no value as a marker of malignancy in follicular lesions, due to both low sensitivity and specificity. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400147     DOI: 10.1002/path.848

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.

Authors:  Sheng-Lan Wang; Wan-Tzu Chen; Ming-Tsang Wu; Hon-Man Chan; Sheau-Fang Yang; Chee-Yin Chai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Authors:  Yongchun Wang; Alan K Meeker; Jeanne Kowalski; Hua-Ling Tsai; Helina Somervell; Christopher Heaphy; Lauren E Sangenario; Nijaguna Prasad; William H Westra; Martha A Zeiger; Christopher B Umbricht
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

3.  Inhibitory effect of all-trans retinoic acid on human hepatocellular carcinoma cell proliferation.

Authors:  Yun-Feng Piao; Yang Shi; Pu-Jun Gao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

5.  Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease.

Authors:  Leticia Bornstein-Quevedo; M L García-Hernández; Ignacio Camacho-Arroyo; Miguel F Herrera; Arturo Angeles Angeles; Ofelia González Treviño; Armando Gamboa-Domínguez
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

7.  Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Paula Soares; Jorge Lima; Ana Preto; Patricia Castro; João Vinagre; Ricardo Celestino; Joana P Couto; Hugo Prazeres; Catarina Eloy; Valdemar Máximo; M Sobrinho-Simões
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

8.  Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules.

Authors:  Leslie R Rowe; Brandon G Bentz; Joel S Bentz
Journal:  Cytojournal       Date:  2006-04-10       Impact factor: 2.091

9.  TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.

Authors:  Jae Kyung Myung; Byung Kuk Kwak; Jung Ah Lim; Myung-Chul Lee; Min Joo Kim
Journal:  Cancer Res Treat       Date:  2015-12-28       Impact factor: 4.679

10.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.